The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1389
April 30, 2012
View Complete Issue         Table of Contents 2019 
Ingenol Mebutate (Picato) for Actinic Keratoses
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ingenol Mebutate (Picato) for Actinic Keratoses
April 30, 2012 (Issue: 1389)
The FDA has approved ingenol mebutate (Picato – Leo) for topical treatment of actinic keratoses (AKs). The new drug is derived from the sap of the Euphorbia peplus plant, a traditional folk remedy for warts and other skin lesions.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ingenol Mebutate (Picato) for Actinic Keratoses
Article code: 1389c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.